Survodutide

Overview

Survodutide is an investigational, lipid-modified peptide designed to activate both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Randomized phase 2 and phase 3 trials have studied body weight, glycaemic measures, MRI-measured liver fat and biopsy-defined MASH endpoints. That is a substantial human evidence base, but it does not make the compound an approved medicine or establish a self-use regimen.

The evidence has to be separated by endpoint. SYNCHRONIZE-1 showed greater 76-week weight reduction than placebo. SYNCHRONIZE-MASLD showed effects on MRI-measured liver fat and weight. A separate biopsy phase 2 trial showed improvement in MASH without worsening fibrosis, but did not establish the PeptideGuide claim of “reversal of liver fibrosis.”

Verified identity and structural boundary

WHO Recommended INN List 90 records survodutide with formula C192H289N47O61. FDA GSRS assigns UNII 2ALA66NS64, CAS 2805997-46-8, and the 29-residue main-chain display HXQGTFTSDYSKYLDERAAKDFIKWLESA. WHO identifies position 2 as 1-aminocyclobutanoyl, and Lys24 carries the lipid-linked side chain. FDA classifies the substance record as a synthetic peptide hormone; that registry identity is not approval.

No single molecular-weight field is promoted. PubChem CID 168429725 uses the same formula and computes 4232 g/mol, while the current FDA GSRS page displays an estimated 3300 Da property and its own validation warning that a different calculation is more than 1% away. Selecting one number without preserving that conflict would create false precision.

These identifiers define a registered molecular structure. They do not verify the identity, purity, sterility, concentration or equivalence of an untested product sold under the same name.

Mechanism, pharmacokinetics and scheduling

Preclinical pharmacology and the human trial programme describe survodutide as a dual GCGR/GLP-1R agonist. The engineered peptide includes a lipid-linked side chain intended to extend exposure. Clinical outcomes still measure the combined investigational product; they do not reveal how much of an observed effect came from each receptor.

The phase 1 paper reports a long terminal half-life that was similar across the tested single-dose groups, but the accessible primary article text reviewed for this page does not provide a sufficiently clear numeric value to protect in frontmatter. PeptideGuide's “weekly” field is therefore not promoted: once-weekly is a protocol schedule, not a measured half-life.

Study arms used subcutaneous products, dose escalation, eligibility criteria, monitoring and stopping rules. Those design features cannot be converted into a personal protocol, and a research material cannot be assumed bioequivalent to the trial product.

Evidence map

Obesity and glycaemic evidence

Phase 2 obesity dose-finding

The 46-week phase 2 obesity trial randomized 387 adults without diabetes; 386 received at least one dose. In the planned-treatment analysis, mean weight changes were −6.2%, −12.5%, −13.2% and −14.9% across the four survodutide groups, versus −2.8% with placebo. Only 60.4% of treated participants completed the 46-week treatment period. Adverse events occurred in 91% of survodutide recipients and 75% of placebo recipients, and gastrointestinal events in 75% and 42%, respectively.

SYNCHRONIZE-1 phase 3

SYNCHRONIZE-1 randomized 725 adults with obesity or overweight plus a complication, excluding diabetes. At week 76, under the treatment-regimen estimand, mean weight change was −12.2% and −13.0% in the two survodutide groups and −5.4% with placebo. At least 5% weight reduction occurred in 72.6%, 71.9% and 46.3%, respectively; both primary comparisons were reported as p<0.001.

Gastrointestinal symptoms occurred in 80.9%, 89.7% and 47.9%, respectively, and were usually mild to moderate. No deaths were reported. This is positive phase 3 efficacy evidence, not a licensed indication or a result for people outside the trial's eligibility and monitoring conditions.

Type 2 diabetes phase 2

The 16-week phase 2 diabetes trial randomized 413 participants taking metformin. Adjusted mean HbA1c changes ranged from −0.91 to −1.71 percentage points across survodutide groups, and mean weight change reached −8.7% in one group. The semaglutide comparator was open-label while the other trial groups were blinded; the paper does not turn this short dose-finding design into a general superiority conclusion. Adverse events were reported in 77.8% of survodutide-treated participants, mainly gastrointestinal.

Liver evidence and the fibrosis boundary

Biopsy phase 2: MASH improved, fibrosis reversal not established

The 48-week phase 2 trial enrolled adults with biopsy-confirmed MASH and F1–F3 fibrosis; 293 participants received at least one dose. Improvement in MASH without worsening fibrosis occurred in 47%, 62% and 43% across the three survodutide groups, versus 14% with placebo. The quadratic dose-response model for the primary endpoint was reported as p<0.001.

At least one-stage fibrosis improvement occurred in 34%, 36% and 34%, versus 22% with placebo. The abstract reports these as a secondary endpoint but does not report a confirmatory significance result for those comparisons. “MASH improvement without worsening fibrosis” and “fibrosis reversal” are not interchangeable; only the former was the positive primary result.

SYNCHRONIZE-MASLD phase 3: MRI endpoints

SYNCHRONIZE-MASLD included 216 adults with obesity and at-risk MASLD, based on non-invasive tests or biopsy-confirmed MASH, randomized 2:1 to survodutide or placebo for 48 weeks. Both co-primary endpoints were met. Under the efficacy estimand, at least 30% MRI-PDFF liver-fat reduction occurred in 84.2% versus 24.3%, and mean weight change was −12.2% versus −1.0% (both p<0.0001). Under the treatment-regimen estimand, the corresponding results were 68.5% versus 28.6% and −8.7% versus −1.4%.

The trial is important, but its co-primary liver endpoint was an MRI-measured fat reduction, not a phase 3 biopsy fibrosis endpoint. The authors list a 48-week duration and recruitment limited to the United States and Spain as limitations. The ongoing LIVERAGE studies are designed to address longer-term MASH, fibrosis, cirrhosis and clinical outcomes; their existence is not a positive result.

Safety and research-integrity boundary

Across the completed trials, gastrointestinal events were common and increased with active treatment in several comparisons. In the phase 2 MASH trial, nausea occurred in 66% versus 23%, diarrhoea in 49% versus 23%, and vomiting in 41% versus 4% with survodutide versus placebo. Serious adverse events occurred in 8% versus 7%. Small or selected studies and follow-up of 16–76 weeks cannot exclude uncommon, subgroup-specific or long-latency harms.

Boehringer Ingelheim funded the major published trials and is the responsible party for the clinical programme. Sponsor involvement does not invalidate randomization or peer review, but it is material when judging replication, endpoint choice, estimands and claims that extend beyond the papers. Results from treatment-regimen and efficacy estimands are kept separate here rather than selecting the more favorable number.

The page also avoids cross-trial ranking. Different eligibility criteria, estimands, dose-escalation rules, follow-up and missing-data handling mean that headline percentages from another incretin study cannot be treated as a head-to-head comparison.

Current programme, regulation, sport and Russian evidence

A bounded ClinicalTrials.gov query for survodutide OR "BI 456906", checked on 21 August 2026, returned 33 records: 25 completed, 4 recruiting, 2 active, not recruiting, and 2 not yet recruiting. The records included 20 phase 1, 4 phase 2 and 9 phase 3 labels. Only 3 had posted structured results in the registry snapshot. Published papers can therefore contain results that a registry record has not yet posted, while a completed record without results cannot be counted as success.

The 5,531-participant SYNCHRONIZE-CVOT record was completed and had no posted structured results in the checked snapshot. The recruiting LIVERAGE and LIVERAGE-Cirrhosis trials had estimated enrolments of 1,800 and 1,590 and no results. Cardiovascular protection and long-term liver benefit therefore remain questions, not established indications.

Boehringer's 2023 annual report describes FDA expedited-development designations and an EMA PRIME designation for the MASH programme. FDA explains that Breakthrough Therapy is a development and review pathway based on preliminary evidence; it is not marketing approval. The current openFDA exact-name drug-approval query returned no survodutide match, and the European Commission Union Register dataset contained no survodutide product entry. No FDA-approved or centrally authorised EU survodutide medicine was identified as of the article date.

A targeted PubMed search for survodutide/BI 456906 with a Russian affiliation returned zero records. A 2026 Russian-language Doctor.Ru review discusses the international phase 2 liver trial; it is secondary literature, not a Russian direct-administration trial. No Russian human trial was promoted from that review.

An exact-name review of the 2026 WADA list found neither survodutide nor BI 456906. The list is not exhaustive, so name absence is not anti-doping clearance and no WADA class is inferred here. Athletes need a current, case-specific determination from the responsible anti-doping authority.

What remains unknown

• Whether the weight and liver-fat effects persist after treatment stops.
• Whether survodutide improves cardiovascular outcomes; the completed CVOT had no posted result in the checked registry snapshot.
• Whether ongoing biopsy and clinical-outcome studies confirm fibrosis, cirrhosis or liver-event benefit.
• The frequency of uncommon and long-latency harms in broader populations.
• How outcomes compare in properly powered head-to-head trials rather than across separate studies.
• Whether any non-trial material matches the registered structure and the study product's identity, purity, sterility, concentration and exposure.

Survodutide should therefore be described as an investigational peptide with positive phase 3 weight and MRI liver-fat evidence, not as an approved medicine, a proven fibrosis-reversal treatment or a self-use protocol.